← Aurinia Pharmaceuticals Inc. (AUPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aurinia Pharmaceuticals Inc. (AUPH)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aurinia Pharmaceuticals (AUPH) is a ~$2.1B market cap specialty pharma with 130 employees, best known for its approved Lupus Nephritis franchise and an expanding pipeline centered on voclosporin. The company returned to profitability in 2025 with $283M in revenue and $287M net income, and holds $40.7M in net cash with low dilution risk. The next scheduled catalyst is Q2 2026 earnings on July 30.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Dry Eye Syndrome |
| Voclosporin High Dose | Phase 2 | Lupus Nephritis |
| Voclosporin | Phase 3 | Lupus Nephritis |
| Ciclosporin | Phase 3 | Psoriasis |
| Voclosporin Ophthalmic Solution | Phase 2 | Dry Eye |
| Aritinercept | Phase 2 | Myasthenia Gravis, Generalized |
Price & technical context
3-month
+2.5%
6-month
+9.2%
12-month
+46.5%
52-wk range
$11.10–$18.62
vs 50-day MA
+1.4%
vs 200-day MA
+4.1%
Realized vol
47.2%
Max drawdown
-31.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AUPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.